CG Oncology Q2 2024 Adj EPS $(0.28) Beats $(0.41) Estimate
Portfolio Pulse from Benzinga Newsdesk
CG Oncology (NASDAQ:CGON) reported a Q2 2024 adjusted EPS of $(0.28), beating the analyst consensus estimate of $(0.41) by 31.71%.
August 08, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CG Oncology reported a Q2 2024 adjusted EPS of $(0.28), which is significantly better than the analyst consensus estimate of $(0.41). This positive earnings surprise of 31.71% is likely to boost investor confidence and could lead to a short-term increase in the stock price.
The better-than-expected earnings report indicates that CG Oncology is performing well relative to analyst expectations. This positive surprise is likely to attract investor interest and could result in a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100